Literature DB >> 31115652

Therapeutic application of the CRISPR system: current issues and new prospects.

Minyoung Lee1, Hyongbum Kim2.   

Abstract

Since its discovery, the Clustered Regularly Interspaced Short Palindromic Repeat (the CRISPR) system has been increasingly applied to therapeutic genome editing. Employment of several viral and non-viral vectors has enabled efficient delivery of the CRISPR system to target cells or tissues. In addition, the CRISPR system is able to modulate the target gene's expression in various ways, such as mutagenesis, gene integration, epigenome regulation, chromosomal rearrangement, base editing and mRNA editing. However, there are still limitations hindering an ideal application of the system: inefficient delivery, dysregulation of the delivered gene, the immune response against the CRISPR system, the off-target effects or the unintended on-target mutations. In addition, there are recent discoveries that have not been yet applied to CRISPR-mediated therapeutic genome editing. Here, we review the overall principles related to the therapeutic application of the CRISPR system, along with new strategies for the further application and prospects to overcome the limitations.

Entities:  

Mesh:

Year:  2019        PMID: 31115652     DOI: 10.1007/s00439-019-02028-2

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  3 in total

Review 1.  Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application.

Authors:  Kateryna Kratzer; Landon J Getz; Thibaut Peterlini; Jean-Yves Masson; Graham Dellaire
Journal:  Hum Genet       Date:  2021-04-08       Impact factor: 4.132

2.  Sequence-specific retrotransposition of 28S rDNA-specific LINE R2Ol in human cells.

Authors:  Yuting Su; Narisu Nichuguti; Azusa Kuroki-Kami; Haruhiko Fujiwara
Journal:  RNA       Date:  2019-08-21       Impact factor: 4.942

Review 3.  Allele-specific genome targeting in the development of precision medicine.

Authors:  Junjiao Wu; Beisha Tang; Yu Tang
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.